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Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed after the disease has metastasized; it is among the most lethal forms of cancer. We recently described aberrant expression of an open reading frame 1 protein, ORF1p, encoded by long interspersed element-1 (LINE-1; L1) retrotransposon, in PDAC 1 . To test whether LINE-1 expression leads to somatic insertions of this mobile DNA, we used a targeted method to sequence LINE-1 insertion sites in matched PDAC and normal samples. We found evidence of 465 somatic LINE-1 insertions in 20 PDAC genomes, which were absent from corresponding normal samples. In cases in which matched normal tissue, primary PDAC and metastatic disease sites were available, insertions were found in primary and metastatic tissues in differing proportions. Two adenocarcinomas secondarily involving the pancreas, but originating in the stomach and duodenum, acquired insertions with a similar discordance between primary and metastatic sites. Together, our findings show that LINE-1 contributes to the genetic evolution of PDAC and suggest that somatic insertions are acquired discontinuously in gastrointestinal neoplasms.
Pancreatic ductal adenocarcinoma (PDAC) affects about 270,000 people worldwide each year and is the fourth most common cause of cancer deaths in the United States. One-and five-year survival rates are 25% and 6%, respectively; most cases are locally advanced or metastatic by the time the disease is recognized clinically. Somatically acquired mutations are central to the development of PDAC. A typical case acquires 50 mutations in protein-coding sequences. These include a few causative (driver) mutations, like KRAS G12D or KRAS G12V , and many inconsequential (passenger) mutations 2, 3 . Most mutations occur while the neoplasm is still localized to the pancreas, before metastasis 4 .
Acquired structural alterations to PDAC genomes are less well characterized. In this study, we focused on long interspersed element-1 retrotransposon insertions. L1 is a mobile genetic sequence that comprises about 17% of the human genome. Most copies are invariant and not competent to transpose. However, some L1 sequences from the L1Hs or L1PA1 families are a significant source of inherited genetic variation and encode endonuclease and reverse-transcriptase activities that promote their propagation in genomes [5] [6] [7] . We recently described expression of ORF1p in 89% of PDACs and 27% of pancreatic intraepithelial neoplasias (PanINs) 1 . In the current study, we tested whether somatic retrotransposition events would be evident in PDAC genomes.
Matched normal tissue and tumor samples were collected postmortem. We extracted gDNA and used one-sided PCR to selectively amplify segments downstream of L1Hs insertions for sequencing, an approach we term transposon insertion profiling by sequencing (TIP-seq) (Fig. 1a) . Similar approaches have been previously reported 8, 9 . Twenty-two individuals donated samples used in this study (Supplementary Table 1 ). All were initially diagnosed with PDAC; this condition was confirmed in 20 cases. Two tumors were reclassified as adenocarcinomas, likely originating in gastric or duodenal sites and secondarily involving the pancreas.
Genomic DNA was digested with restriction enzymes, ligated to vectorette oligonucleotides and amplified using a primer specific to the 3′ UTR of L1Hs repeats (Fig. 1b) . Amplicons were sheared and sequenced to an average read count of 43 million, and sequences were aligned to the reference genome assembly. We identified most of the L1Hs in the reference genome in all samples (averaging 400 elements in the top 500 peaks, range 390-413; Supplementary Table 2) . As expected, many known inherited polymorphisms were also seen.
After subtracting the known germline variants, read pile-ups (peaks) from normal tissue TIP-seq indicated novel constitutional L1Hs insertions. We examined these loci for potential roles in cancer risk.
Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma
No exonic LINE-1 could be sequence verified. No insertions were seen in the familial pancreatic cancer genes, breast cancer 2, early onset (BRCA2) 10 ; partner and localizer of BRCA2 (PALB2) 11 ; protease, Ser1 (PRSS1) 12 ; or cyclin-dependent kinase inhibitor 2 (CDKN2) 13 .
To identify somatically acquired insertions, we compared TIP-seq profiles of matched tumor and normal gDNA samples. We found a total of 268 cancer-specific insertions in 18 cases of primary PDAC (Fig. 2a, Supplementary Tables 3 and 4) . There was substantial variability between cases in the numbers of somatic insertions identified (range 0-65; average 15 insertions per case).
To identify somatic insertions at sites of metastatic PDAC, we assayed 15 metastases in 15 cases and found 242 insertion candidates that were not present in the corresponding normal tissue samples (range 0-42, average 16 insertions per site). In 13 cases with both primary and metastatic cancers available, we found 45 insertions shared between the two sites of disease. One case harbored 23 of these shared insertions (Figs. 2b and 3, Supplementary Tables 3 and 4) .
The expression level of the ORF1p LINE-1, as scored by immunohistochemistry, correlated with the number of somatically acquired LINE-1 insertions, albeit not to a statistically significant degree (P = 0.07). Survival after diagnosis was inversely correlated with somatically acquired LINE-1 insertions present in the primary tumor and with ORF1p immunoreactivity (P = 0.025 and P = 0.03, respectively) ( Fig. 2c-e) .
Two cases of adenocarcinoma that infiltrated the pancreas, but were later recognized to have originated in nearby stomach and small bowel, were also included. We found evidence for 51 and 63 somatic LINE-1 insertions in these PDAC mimics.
TIP-seq reads cover only the 3′ end of L1Hs insertions. To validate and sequence the entirety of somatically acquired insertions, we designed PCR primers for regions flanking predicted insertion sites. We Sanger sequenced amplicons that were larger than those corresponding to the pre-insertion, or 'empty' , site present in tumor and absent from normal tissue. In total, 117 loci were considered; 92 were in a region that allowed primer design and had short-read sequences consistent with a LINE-1 insertion by manual review. Of these, 81 insertions (88%) could be PCR validated; for 75 (81%), we Table 5 ). These show expected hallmarks of somatic retrotransposition (Fig. 1c) 14 . All insertions are 5′ truncated with an average size of approximately 1 kb; the average target site duplication (TSD) is 11 bp. Inverted or reversed orientation of the 5′ L1Hs segment was commonly seen 15 ( Supplementary Fig. 1, Supplementary Table 6 ). Transduction events of sufficient size to identify the templating element 16 were recovered in two instances. Both were found in the same PDAC case and reflect activity of a known active element on 14q23.1 (ref. 17) , which copied a 324-bp segment 3′ of its insertion site to positions on chromosomes 9 and 16 during development of the primary tumor (Supplementary Table 5) .
We next used somatic LINE-1 insertion numbers to infer rates of retrotransposition during the development and dissemination of PDAC. For this, we applied a model described for this disease that relates mutation rate to the rate of cell division, numbers of acquired neutral mutations and time 4 . We expect that insertions shared between primary and metastatic samples of a case arose in the progenitor lineage of the primary tumor. These probably occurred after a genetic growth advantage was acquired by the primary tumor, but before a cell existed there with all of the insertions that would be carried to the metastatic site. Six cases, all of which had somatic LINE-1 insertions shared in primary and metastatic tissues, were considered. In aggregate, 259 independent insertions were found in these cases, with 45 LINE-1 found in both the primary tumor and the sampled metastatic site. Numbers of shared insertions (N) ranged from 1 to 23 (average, 7.5), reflecting retrotransposition rates in progenitor lineages ranging from 0.5 to 12.4 insertions per 1,000 cell doublings (average, 4.0).
In contrast, we expected that the 82 insertions identified at metastatic sites but not the corresponding primary tumors had occurred later than had shared insertions. To test this in one case, we attempted to amplify eight of these insertions in six additional metastatic lesions. Four insertions (4 of 8) were uniquely amplified in the single metastasis (Fig. 3c) . Four were found in two additional metastases (totaling 3 of 7 lesions). The latter insertions were acquired in the primary tumor in a subclone that would seed multiple metastases, though as a comparably late event (i.e., subsequent to the birth of the progenitor clone). None were detected in the primary tumor. Overall, these findings Interestingly, within each PDAC case, we found no concordance between retrotransposition rates for these two phases of disease (Fig. 3b) . This is also true of primary and metastatic diseases originating in the tubular gastrointestinal tract, assuming a similar pace of disease spread. The gastric adenocarcinoma case had many shared insertions (Fig. 3e) and disproportionately acquired these in the progenitor lineage of the primary tumor; its metastatic site had little evidence of continued retrotransposition. Conversely, the duodenal tumor accrued few somatic LINE-1 insertions in the progenitor lineage but produced a progressor clone that acquired many new insertions (Fig. 3f) . These data suggest to us that retrotransposition occurs discontinuously during tumor evolution.
To test for concordance between acquired single-nucleotide changes and LINE-1 insertions, we compared proportions of shared (i.e., primary and metastasis) and metastasis-only alterations in a single PDAC case. Single-nucleotide mutations were detected by exome sequencing. For single-nucleotide mutations, we found a ratio of shared to metastasis-only mutations of approximately 60:40 (61:39). This is similar to ratios previously reported 4 . The ratio is essentially reversed for LINE-1 insertions in the same PDAC case (43:57) (Fig. 3d) . The discrepancy in the proportions of single-nucleotide mutations and LINE-1 insertions found provides additional evidence of asynchrony in the rates of these two mutational mechanisms.
Somatic LINE-1 insertions accumulate throughout PDAC genomes. Although loosely aggregated on individual chromosomes in some cases, hotspots for integration were not readily appreciated when all sites were considered (Fig. 4a) . No exonic insertions were found.
Intronic insertions were seen in 202 genes. Gene set enrichment analysis does not clearly implicate specific pathways required for tumor development. Together, these data indicate that LINE-1 insertions are not commonly canonical 'driver' mutations and that any one insertion is probably dispensable for tumorigenesis.
To explore the possibility that insertions influence gene expression, we prioritized insertions that occurred in close proximity to exons or potential regulatory sites as indicated by ENCODE project annotations. One example is a somatic LINE-1 insertion that we detected in an intron of apoptotic protease activating factor 1 (APAF1); it is a 443-bp insertion with an inverted and truncated 5′ end. The L1 is located in a small intron (1.6 kb) of the APAF1 gene, adjacent to a DNase-hypersensitive region that can be bound by transcription factors. We used PCR to detect the insertion in the primary tumor and in all seven metastatic disease sites sampled in the same case. Immunohistochemistry to evaluate APAF1 protein showed a variegated pattern of expression in the primary tumor sample in this case (Fig. 4b-e) , whereas other tumors displayed uniform APAF1 immunoreactivity. Repeated attempts to amplify the insertion from microdissected sectors of the tissue were unsuccessful. Our findings are consistent with an acquired event altering APAF-1 expression in this case. However, they do not exclude other underlying mechanisms nor imply that this is a common feature in pancreatic cancers.
To date, targeted studies have demonstrated LINE-1 retrotransposition in lung 8 , colon 18 and hepatocellular 19 carcinoma, and whole-genome sequencing from the Cancer Genome Atlas (TCGA) 20, 21 and the International Cancer Genome Consortium (ICGC) 22 has shown more broadly that human malignancies of various origins are characterized by different levels of L1 activity. Our work adds pancreatic cancer to this picture. We show that PDAC is highly active for retrotransposition, and, moreover, that single lineages acquire multiple LINE-1 integrations over their evolution. npg l e t t e r s 1 0 6 4 VOLUME 21 | NUMBER 9 | SEPTEMBER 2015 nature medicine
The variability in numbers of acquired insertions between PDAC cases is similar to that previously described for other types of tumors. We have ascribed this to differences in each person's inherited complement of active LINE-1 or to tumor-specific idiosyncrasies of retrotransposon control, but we expected new insertions to be acquired steadily during the course of disease. Our discovery of discordant overall rates of retrotransposition in matched progenitor and progressor subclones challenges this assumption. Similarly, in cases for which single-nucleotide mutation data are available, we find a lack of concordance between proportions of single-nucleotide mutations and LINE-1 insertions occurring in different phases of disease. Our findings suggest that LINE-1 insertions in gastrointestinal-tract cancers occur discontinuously. This is consistent with variable activity of individual LINE-1 elements previously reported in prostate cancer and lung cancer 22 . Cellular mechanisms restricting somatic retrotransposition are not well understood, and perhaps the discontinuity that we see in the timing of insertions is a result of discrete breaches in host defenses. Tumors with many insertions could have acquired these in a series of breaches or even in isolated catastrophic episodes that can be likened to chromothripsis in cancer genomes 23 .
Although many LINE-1 insertions can occur in metastatic progenitor lineages, they seem to be dispensable for PDAC. Some cases had no evidence of retrotransposition, and we have no evidence of recurrent insertion sites or exonic insertions. Although we cannot definitively assign a function to acquired LINE-1 insertions, our findings leave open the possibility that somatically acquired LINE-1 insertions influence gene regulation and contribute to cancer-cell phenotypes. Emerging technologies, such as single cell LINE-1 insertion site sequencing 24 and phenotyping, should yield unprecedented opportunities to understand the timing of LINE-1 insertion events and how they contribute to genetic and phenotypic heterogeneity in cancer.
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